Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. Standard treatment for newly diagnosed fit AML patients is intensive chemotherapy. Rel

Smoldering Multiple Myeloma – to treat or not to treat?

Feb 7th, 2024 26m 5s

Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering

Thalassemia - a blind spot

Feb 2nd, 2024 40m 32s

Thalassemia is a hereditary blood disorder, in which the synthesis of hemoglobin chains is impaired. Consequently, people with thalassemia minor may have slight to severe anemia which usually does not cause any problems. Thalassemia major in c

Causes, symptoms and diagnosing ASMD – A rare lysosomal storage disorder

Oct 31st, 2023 38m 17s

Today we will discuss a rare, inherited metabolic disorder known as ASMD, acid sphingomyelinase deficiency (or historically known as Niemann-Pick types A, A/B, and B). This genetic condition is very rare. It can be diagnosed, after suspicion, b

MGRS- Monoclonal Gammopathy of Renal Significance

Oct 26th, 2023 25m 40s

Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a

Sickle cell disease - A hereditary blood disorder

Jul 7th, 2023 1h 2m

Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells

Extramedullary disease in Multiple Myeloma

Jul 7th, 2023 22m 39s

Extramedullary disease (EMD) represents an aggressive form of multiple myeloma, characterized by the ability of myeloma cells to form tumors outside the bone marrow independently. Scientific research is continuously evolving, leading to discov

Recent findings in MGUS

Apr 15th, 2023 44m 10s

Monoclonal gammopathy of undetermined significance, called MGUS, is a blood condition which indicates occurrence of clonal cells that secrete monoclonal immunoglobulins. MGUS as such, is not a harmful disease, and usually doesn’t require treatm

Waldenström Macroglobulinemia: a clinical update

Mar 27th, 2023 43m 3s

Waldenström Macroglobulinemia is a rare type of non-Hodgkin lymphoma affecting B-cells. Waldenström Macroglobulinemia is characterised by high levels of circulating antibodies, immunoglobulin M, which is made and secreted by the cells involved

Mental health during and after cancer treatment

Dec 14th, 2022 40m 20s

Mental health includes our emotional, psychological and social well-being. A physical illness can have a severe impact on mental health. As health care professionals we often focus primarily on treatment and how to handle side effects and compl

Challenges in diagnosing Gaucher and other rare inherited metabolic disorders

Oct 18th, 2022 37m 6s

In this episode we will discuss rare, inherited metabolic disorders in general, as well diseases such as Gaucher and other diseases. These genetic conditions are very rare. They can be diagnosed, after suspicion, by different screening test. Bu

Hemoglobinopathies

Jan 30th, 2022 36m 29s

Hemoglobinopathies have previously been rare in the Nordic population but with increasing migration we now meet many patients with different types of thalassemias and hemoglobin variants. It is important to recognize these conditions and diagno

MRD as primary endpoint

Nov 29th, 2021 40m

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be

Minimal Residual Disease (MRD) - Cost vs Benefit

Oct 28th, 2021 27m 39s

Detection of Minimal Residual Disease (MRD) is becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through in

AI - The future of pathology?

Jul 1st, 2021 26m 6s

One drop of blood, two sheets of glass, 40x objective. Hematological diagnostics demands a keen eye and sound reasoning. At the same time, artificial intelligence is entering the field in a big way. We ask: are the days of Giemsa coloring past

It’s in the Genes

Jul 1st, 2021 31m 58s

We’re currently able to scan the entire human genome in a single day, and the application of genetic sequencing has the potential to improve diagnosis, prognosis and treatment. Ahead lies the opportunity to easily discover rare hematological di

aTTP

Apr 27th, 2021 24m 16s

aTTP is a hematological disease so rare that all professionals struggle to identify it. In this episode, we talk to a hematologist who has diagnosed and treated a patient with aTTP, and we discover what actions a hematologist takes, when facing

Teaser: The Hematology Podcast

Apr 27th, 2021 52s

In The Hematology Podcast, we dig into the clinical, the theoretical, and the practical, as we discuss the past, present, and future of the hematological field. MAT-BE-2200979 (ver. 1 ) 12 2022

Rate